Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.
作者信息
Rizzo Alessandro
机构信息
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II,", Viale Orazio Flacco 65, Bari, 70124, Italy.
出版信息
Br J Cancer. 2022 Nov;127(8):1381-1382. doi: 10.1038/s41416-022-01929-w. Epub 2022 Sep 5.
Abstract
摘要
相似文献
1
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.确定高程序性死亡配体1（PD-L1）表达的晚期非小细胞肺癌的最佳一线治疗方案：一个存在争议的问题。
Br J Cancer. 2022 Nov;127(8):1381-1382. doi: 10.1038/s41416-022-01929-w. Epub 2022 Sep 5.
2
Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.回复：确定高程序性死亡配体1（PD-L1）表达的晚期非小细胞肺癌的最佳一线治疗方案：一个存在争议的问题。
Br J Cancer. 2022 Nov;127(8):1383-1384. doi: 10.1038/s41416-022-01930-3. Epub 2022 Sep 5.
3
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].非小细胞肺癌中PD-1与PD-L1表达及表皮生长因子受体突变的相关性研究
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):623-631. doi: 10.3779/j.issn.1009-3419.2021.102.31. Epub 2021 Aug 30.
4
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.采用靶向下一代测序技术对非小细胞肺癌患者进行分析，明确了对抗程序性细胞死亡蛋白 1（PD-1）和抗程序性死亡配体 1（PD-L1）阻断治疗的反应的分子决定因素。
J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.
5
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?非小细胞肺癌中PD-1/PD-L1阻断疗法的生物标志物：PD-L1表达是患者选择的良好标志物吗？
Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6.
6
PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.PD-1/PD-L1 抑制剂治疗晚期非小细胞肺癌患者的 PD-L1 表达和 EGFR 状态：一项荟萃分析。
Future Oncol. 2019 May;15(14):1667-1678. doi: 10.2217/fon-2018-0639. Epub 2019 May 1.
7
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.抗 PD-1 抗体在 EGFR 突变和高 PD-L1 表达的 NSCLC 患者中的疗效。
J Cancer Res Clin Oncol. 2021 Jan;147(1):245-251. doi: 10.1007/s00432-020-03329-0. Epub 2020 Jul 23.
8
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.
9
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].[PD-1/PD-L1检查点抑制剂治疗非小细胞肺癌的临床研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):440-448. doi: 10.3779/j.issn.1009-3419.2019.07.06.
10
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
引用本文的文献
1
The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis.驱动基因阴性的非小细胞肺癌肝转移患者免疫联合治疗的疗效和安全性：一项系统评价和网状Meta分析
BMC Cancer. 2025 Aug 18;25(1):1332. doi: 10.1186/s12885-025-14712-w.
2
Feasibility of machine learning-based modeling and prediction to assess osteosarcoma outcomes.基于机器学习的建模和预测评估骨肉瘤预后的可行性。
Sci Rep. 2025 May 19;15(1):17386. doi: 10.1038/s41598-025-00179-z.
3
Unraveling the anti-tumor effects of midazolam in non-small cell lung cancer through the lncRNA XLOC_010706/miR-520d-5p/STAT3/autophagy pathway.通过lncRNA XLOC_010706/miR-520d-5p/STAT3/自噬通路揭示咪达唑仑在非小细胞肺癌中的抗肿瘤作用
Sci Rep. 2025 May 14;15(1):16796. doi: 10.1038/s41598-025-01625-8.
4
Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach.病例报告：帕博利珠单抗联合化疗对一名胃转移性肝样腺癌患者的二线治疗良好疗效
Front Pharmacol. 2025 Apr 1;16:1387661. doi: 10.3389/fphar.2025.1387661. eCollection 2025.
5
A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma.一种新型肿瘤相关巨噬细胞风险特征可预测肺腺癌的预后和免疫治疗反应。
Am J Cancer Res. 2025 Mar 15;15(3):876-893. doi: 10.62347/SQUF6988. eCollection 2025.
6
Enhancement of Prognostic Outcomes in Stage III Non-Small Cell Lung Cancer: A Retrospective Study on Neoadjuvant Immuno-Chemotherapy Followed by Definitive Chemo-Radiotherapy.III期非小细胞肺癌预后结果的改善：一项关于新辅助免疫化疗后序贯根治性放化疗的回顾性研究
Transl Oncol. 2025 Jun;56:102394. doi: 10.1016/j.tranon.2025.102394. Epub 2025 Apr 11.
7
Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma.肿瘤源性免疫球蛋白样转录物3的抑制重塑免疫抑制性肿瘤微环境并增强肺腺癌中程序性细胞死亡配体1阻断免疫疗法的效果。
Transl Oncol. 2025 Jun;56:102381. doi: 10.1016/j.tranon.2025.102381. Epub 2025 Apr 8.
8
Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs.通过用优化的串联双OX40L信使核糖核酸激活T细胞增强抗肿瘤免疫力
Int J Nanomedicine. 2025 Mar 19;20:3607-3621. doi: 10.2147/IJN.S479434. eCollection 2025.
9
Evaluation of a novel ensemble model for preoperative ovarian cancer diagnosis: Clinical factors, O-RADS, and deep learning radiomics.一种用于术前卵巢癌诊断的新型集成模型评估：临床因素、O-RADS和深度学习影像组学
Transl Oncol. 2025 Apr;54:102335. doi: 10.1016/j.tranon.2025.102335. Epub 2025 Mar 5.
10
A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer.一项针对非小细胞肺癌基线脑转移患者的放疗联合免疫治疗的回顾性研究。
Sci Rep. 2025 Feb 27;15(1):7036. doi: 10.1038/s41598-025-91863-7.
本文引用的文献
1
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.NCCN 指南解读：非小细胞肺癌，第 1.2020 版。
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059.
2
The biology and management of non-small cell lung cancer.非小细胞肺癌的生物学特性与治疗管理。
Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183.
3
Network meta-analysis: an introduction for clinicians.网状Meta分析：临床医生指南
Intern Emerg Med. 2017 Feb;12(1):103-111. doi: 10.1007/s11739-016-1583-7. Epub 2016 Dec 2.
Zotero 插件